Amytrx Therapeutics Welcomes Two Renowned Scientists to its Board of Directors
07 Nov 2023 //
PR NEWSWIRE
Amytrx Therapeutics` AMTX-100 Phase 1 Trial Data Presented at Conference
25 Jul 2023 //
PR NEWSWIRE
Amytrx Announces Open Enrollment for Phase 2b Clinical Trial of AMTX-100 CF3
28 Jun 2023 //
PR NEWSWIRE
Amytrx Tx Partners With AmbioPharm to Expand Anti-Inflammatory Peptides
27 Jul 2022 //
BUSINESSWIRE
Amytrx`s AMTX-100 CF3 Moves to Phase II Clinical Trial for Atopic Dermatitis
09 Jun 2022 //
PRNEWSWIRE
Highly secretive inflammation biotech secures final tranche of Series A round
26 May 2022 //
ENDPTS
Amytrx Tx raises $18M for new therapeutic interventions of atopic dermatitis
25 May 2022 //
PRNEWSWIRE